RGLS:NSD-Regulus Therapeutics Inc.

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing Price

USD 1.45

Change

-0.05 (-3.33)%

Market Cap

USD 0.01B

Volume

0.08M

Average Target Price

USD 1.40 (-3.45%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Regulus Therapeutics Inc is a biopharmaceutical company. The Company is engaged in discovering and developing first-in-class drugs that target microRNAs to treat various diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-11-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

-0.01 (-0.01%)

USD 122.06B
GILD Gilead Sciences Inc.

+0.43 (+0.61%)

USD 91.74B
BIIB Biogen Inc.

+0.18 (+0.06%)

USD 64.29B
SHPG Shire plc

-1.09 (-0.60%)

USD 55.14B
CELG Celgene Corporation

-0.78 (-1.10%)

USD 49.12B
VRTX Vertex Pharmaceuticals Incorpo..

-2.54 (-1.47%)

USD 43.52B
REGN Regeneron Pharmaceuticals Inc.

-4.46 (-1.29%)

USD 37.03B
ALXN Alexion Pharmaceuticals Inc.

-0.08 (-0.07%)

USD 26.44B
BMRN BioMarin Pharmaceutical Inc.

+0.45 (+0.48%)

USD 16.65B
GRFS Grifols S.A.

+0.43 (+2.08%)

USD 14.45B

ETFs Containing RGLS

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -88.38% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -88.38% 3% F 1% F
Trailing 12 Months  
Capital Gain -86.79% 3% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -86.79% 3% F 2% F
Trailing 5 Years  
Capital Gain -97.95% 7% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.95% 7% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -27.41% 12% F 5% F
Dividend Return -27.41% 12% F 5% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 68.65% 31% F 11% F
Risk Adjusted Return -39.93% 24% F 14% F
Market Capitalization 0.13B 5% F 6% F

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -0.26 16% F 56% F
Price/Book Ratio 1.22 76% C 70% C-
Price / Cash Flow Ratio -0.06 13% F 65% D
Price/Free Cash Flow Ratio -0.25 13% F 56% F
Management Effectiveness  
Return on Equity -311.50% 5% F 2% F
Return on Invested Capital -299.49% 4% F 2% F
Return on Assets -97.56% 15% F 5% F
Debt to Equity Ratio 385.50% 4% F 5% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

RGLS:NSD-Regulus Therapeutics Inc.

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing Price

USD 1.45

Change

-0.05 (-3.33)%

Market Cap

USD 0.01B

Volume

0.08M

Average Target Price

USD 1.40 (-3.45%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-11-13